Aelis Farma SA
PAR:AELIS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.8
13.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AELIS stock under the Base Case scenario is 1.25 EUR. Compared to the current market price of 2.82 EUR, Aelis Farma SA is Overvalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aelis Farma SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AELIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aelis Farma SA
Balance Sheet Decomposition
Aelis Farma SA
Current Assets | 38.6m |
Cash & Short-Term Investments | 34.4m |
Receivables | 3.9m |
Other Current Assets | 347k |
Non-Current Assets | 616k |
PP&E | 176k |
Intangibles | 190k |
Other Non-Current Assets | 250k |
Current Liabilities | 15.8m |
Accounts Payable | 2.4m |
Accrued Liabilities | 668k |
Other Current Liabilities | 12.7m |
Non-Current Liabilities | 3.6m |
Long-Term Debt | 1.4m |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
Aelis Farma SA
Revenue
|
7.6m
EUR
|
Operating Expenses
|
-15.2m
EUR
|
Operating Income
|
-7.7m
EUR
|
Other Expenses
|
658k
EUR
|
Net Income
|
-7m
EUR
|
Free Cash Flow Analysis
Aelis Farma SA
EUR | |
Free Cash Flow | EUR |
AELIS Profitability Score
Profitability Due Diligence
Aelis Farma SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Aelis Farma SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
AELIS Solvency Score
Solvency Due Diligence
Aelis Farma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Aelis Farma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AELIS Price Targets Summary
Aelis Farma SA
According to Wall Street analysts, the average 1-year price target for AELIS is 9.28 EUR with a low forecast of 4.04 EUR and a high forecast of 14.91 EUR.
Dividends
Current shareholder yield for AELIS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AELIS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Contact
IPO
Employees
Officers
The intrinsic value of one AELIS stock under the Base Case scenario is 1.25 EUR.
Compared to the current market price of 2.82 EUR, Aelis Farma SA is Overvalued by 56%.